GlassScriptPhysician profile
Charles Wilson
NPI 1558311431
$6,684.48
in general payments reported to CMS, 2019-2025
33 companies · $887 in 2025
The $887 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $1,299 · 2021: $777 · 2022: $847 · 2023: $2,276 · 2024: $461 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562 · Travel and Lodging: $1,036 · Consulting Fee: $26.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.78 |
| Travel and Lodging | $1,036.22 |
| Consulting Fee | $26.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,340.57 | 2023-2024 | |
| Medical Device Business Services, INC. | $1,018.03 | 2020 | |
| Acclarent, INC | $619.79 | 2020-2023 | Trudi Nav Cable, Relieva Spinplus, Acclarent Aera |
| Glaxosmithkline, LLC. | $473.69 | 2019-2025 | Nucala |
| Csl Behring | $466.13 | 2020-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $461.19 | 2022-2025 | Dupixent |
| Genzyme Corporation | $359.62 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $254.80 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $223.36 | 2021-2025 | Cuvitru, Eohilia |
| Integra Lifesciences Corporation | $205.16 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Grifols USA, LLC | $163.06 | 2022-2024 | Xembify |
| Lilly USA, LLC | $100.16 | 2022 | |
| Genentech USA, INC. | $99.18 | 2023-2025 | Xolair |
| Pfizer INC. | $90.02 | 2020-2023 | |
| Ionis Pharmaceuticals, INC. | $89.55 | 2025 | Dawnzera |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $80.17 | 2022-2023 | Tezspire |
| Biocryst US Sales Co., LLC | $78.85 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $74.12 | 2020-2021 | |
| Abbvie INC. | $67.16 | 2021-2022 | |
| Horizon Therapeutics Plc | $65.00 | 2019 | |
| Merck Sharp & Dohme LLC | $50.44 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.77 | 2019-2022 | |
| Optinose US, INC. | $38.72 | 2019-2021 | |
| Stryker Corporation | $36.46 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $28.44 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $26.13 | 2025 | |
| Medtronic, INC. | $23.61 | 2022 | |
| Davol INC. | $20.69 | 2023 | Arista Ah Flexitip |
| Arbor Pharmaceuticals, INC. | $18.15 | 2019 | |
| Incyte Corporation | $17.23 | 2022 | |
| Eyevance Pharmaceuticals LLC | $17.18 | 2021 | |
| Ibsa Pharma INC. | $16.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.